Table 3.
Diagnostic utility of pleural IGRA, ADA, CEA and their integrations for the discriminating diagnosis of TPE and MPE
| Assays | TPE | MPE | Sensitivity (95%CI) | Specificity (95%CI) | PPV (95%CI) | NPV (95%CI) | ||
|---|---|---|---|---|---|---|---|---|
| n | Positivity, n(%) | n | Positivity, n(%) | |||||
| Pleural IGRA or ADA | 138 | 133 (96.38) | 58 | 41 (70.69) | 0.96 (0.92–0.99) | 0.29 (0.18–0.43) | 0.76 (0.69–0.83) | 0.77 (0.55–0.92) |
| Pleural IGRA and ADA | 138 | 113 (81.88) | 58 | 1 (1.72) | 0.82 (0.74–0.88) | 0.98 (0.91–1.00) | 0.99 (0.95–1.00) | 0.70 (0.58–0.79) |
| Pleural IGRA or CEA | 128 | 127 (99.21) | 53 | 37 (69.81) | 0.99 (0.96–1.00) | 0.31 (0.18–0.44) | 0.77 (0.70–0.84) | 0.94 (0.71–1.00) |
| Pleural IGRA and CEA | 128 | 111 (86.72) | 53 | 0 (0) | 0.87 (0.80–0.92) | 1.00 (0.93–1.00) | 1.00 (0.97–1.00) | 0.76 (0.64–0.85) |
Abbreviations: IGRA IFN-γ release assay, ADA adenosine deaminase, CEA arcinoembryonic antigen, PPV positive predictive value, NPV negative predictive value. The optimal cutoff values of the pleural ADA, CEA, IGRA stimulated with ESAT6 and peptide were 35.0 IU/L, 2.02 μg/L, 87 SFCs and 62.5 SFCs respectively